Ribociclib for the treatment of hormone-positive HER2-negative breast cancer

Ribociclib for the treatment of hormone-positive HER2-negative breast cancer

Breast cancer steadily holds leading market positions in the malignancy morbidity and mortality pattern. The treatment of metastatic breast cancer remains an extremely topical issue, when its aim is not only to prolong the patient’s life, but also to preserve its quality. Due to advances in molecula...

Full description

Bibliographic Details
Main Authors:	I. P. Ganshina, D. A. Filonenko, O. O. Gordeeva, E. V. Lubennikova, I. V. Kolyadina, A. A. Mescheryakov
Format:	Article
Language:	Russian
Published:	Remedium Group LLC 2019-06-01
Series:	Медицинский совет
Subjects:	breast cancer ribociclib endocrinotherapy
Online Access:	https://www.med-sovet.pro/jour/article/view/3055

Similar Items

Role of palbociclib in the treatment of hormone receptor-positive HER2-negative metastatic breast cancer. Generalizing results of randomized trials and real clinical practice
by: L. G. Zhukova, et al.
Published: (2019-06-01)

Cost-Effectiveness of Ribociclib for Hormone Receptor-Positive HER2-Negative Advanced Breast Cancer
by: Yang J, et al.
Published: (2020-12-01)

Ribociclib in patient with hormone-positive HER2-negative breast cancer with brain metastases: a case report
by: N. S. Prizova, et al.
Published: (2022-06-01)

Ribociclib in the Treatment of Hormone-Receptor Positive/HER2-Negative Advanced and Early Breast Cancer: Overview of Clinical Data and Patients Selection
by: Parati MC, et al.
Published: (2022-04-01)

PHARMACOECONOMIC EVALUATION OF RIBOCICLIB FOR THE FIRST-LINE TREATMENT OF HR-POSITIVE HER2-NEGATIVE ADVANCED BREAST CANCER
by: N. A. Avksentyev, et al.
Published: (2018-08-01)

Ribociclib in the first-line therapy for metastatic hormone-dependent HER2-negative breast cancer in patients with intact ovarian function
by: S. F. Menshikova, et al.
Published: (2018-11-01)

Ribociclib in the treatment of HR+ HER2-negative metastatic breast cancer: updated results from the randomized clinical trials and their role in the clinical practice
by: I. V. Kolyadina
Published: (2021-09-01)

Cost-effectiveness of Ribociclib in HER2- negative breast cancer: A synthesis of current evidence
by: Wedad H. Alotaibi, et al.
Published: (2022-08-01)

Pharmacoeconomic analysis of using cyclin-dependent kinase 4 and 6 inhibitors in the first line treatment of HR-positive HER2-negative advanced breast cancer
by: N. A. Avxentyev, et al.
Published: (2020-02-01)

The Role of the CDK4/6 Inhibitor Ribociclib in Locally Advanced and Oligometastatic Hormone Receptor Positive, Her2 Negative, Advanced Breast Cancer: Case Series and Review of the Literature
by: Andrea Botticelli, et al.
Published: (2022-02-01)

Anti-hormonal maintenance treatment with the CDK4/6 inhibitor ribociclib after 1st line chemotherapy in hormone receptor positive / HER2 negative metastatic breast cancer: A phase II trial (AMICA)
by: Thomas Decker, et al.
Published: (2023-12-01)

Adequate effectiveness of ribociclib plus letrozole or fulvestrant in patients with advanced or metastatic hormone receptor-positive, human epidermal growth factor receptor 2-negative breast cancer treated in routine Bulgarian clinical practice
by: Manoela Manova, et al.
Published: (2023-03-01)

Clinical Outcomes of Patients Treated with Ribociclib in Combination with Aromatase Inhibitors or Fulvestrant for HR-Positive, HER2-Negative Metastatic Breast Cancer, Real-World Data from a Low-Resourced Country
by: Abdel-Razeq H, et al.
Published: (2024-09-01)

Real-World Clinical Outcomes of Ribociclib in Combination with a Non-Steroidal Aromatase Inhibitor and a Luteinizing Hormone-Releasing Hormone Agonist in Premenopausal HR+/HER2− Advanced Breast Cancer Patients: An Italian Managed Access Program
by: Nicoletta Staropoli, et al.
Published: (2022-09-01)

Clinical aspects of the use of ribociclib
by: A. A. Markovich, et al.
Published: (2020-07-01)

Comparative effectiveness analysis of survival with first-line palbociclib or ribociclib plus AI in HR + /HER2- advanced breast cancer (CEPRA study): preliminary analysis of real-world data from Thailand
by: Thanate Dajsakdipon, et al.
Published: (2024-08-01)

Matching-adjusted indirect treatment comparison of ribociclib and palbociclib in HR+, HER2− advanced breast cancer
by: Tremblay G, et al.
Published: (2018-05-01)

Escalation of adjuvant endocrine therapy for early hormone-dependent HER2-negative breast cancer: to whom, when and why?
by: I. V. Kolyadina
Published: (2024-05-01)

Ribociclib-induced vitiligo in a case of metastatic carcinoma of the breast
by: Abhira Deb, et al.
Published: (2025-01-01)

Ribociclib plus letrozole in patients with hormone receptor-positive, HER2-negative advanced breast cancer with no prior endocrine therapy: subgroup safety analysis from the phase 3b CompLEEment-1 trial
by: Borstnar Simona, et al.
Published: (2022-05-01)

Ribociclib plus letrozole in subgroups of special clinical interest with hormone receptor–positive, human epidermal growth factor receptor 2–negative advanced breast cancer: Subgroup analysis of the phase IIIb CompLEEment-1 trial
by: Paul Cottu, et al.
Published: (2022-04-01)

Proton pump inhibitors may reduce the efficacy of ribociclib and palbociclib in metastatic breast cancer patients based on an observational study
by: Kadir Eser, et al.
Published: (2022-05-01)

Updated overall survival from the MONALEESA-3 trial in postmenopausal women with HR+/HER2− advanced breast cancer receiving first-line ribociclib plus fulvestrant
by: P. Neven, et al.
Published: (2023-08-01)

Palinopsia associated with the CDK4/6 inhibitor ribociclib during the first-line treatment of metastatic breast cancer: two case reports
by: Tamara Martos, et al.
Published: (2024-12-01)

Olaparib in the metastatic HER2-negative breast cancer setting
by: L. G. Zhukova, et al.
Published: (2020-12-01)

Safety and efficacy of ribociclib plus letrozole in patients with HR+, HER2– advanced breast cancer: Results from the Spanish sub-population of the phase 3b CompLEEment-1 trial
by: Javier Salvador Bofill, et al.
Published: (2022-12-01)

Exploring treatment with Ribociclib alone or in sequence/combination with Everolimus in ER+HER2−Rb wild-type and knock-down in breast cancer cell lines
by: Oliviero Marinelli, et al.
Published: (2020-11-01)

Ribociclib-Induced Vitiligo: A Case Report
by: Nicolás Silvestre Torner, et al.
Published: (2022-05-01)

Comparative cost-effectiveness analysis of CDK4/6 inhibitors in the first-line treatment of HR-positive and HER2-negative advanced breast cancer: a Markov's model-based evaluation
by: Shereen Elazzazy, et al.
Published: (2024-07-01)

Does Proton Pump Inhibitors Decrease the Efficacy of Palbociclib and Ribociclib in Patients with Metastatic Breast Cancer?
by: Hatice Odabas, et al.
Published: (2023-03-01)

Concomitant administration of proton pump inhibitors does not significantly affect clinical outcomes in metastatic breast cancer patients treated with ribociclib
by: Marzia Del Re, et al.
Published: (2022-12-01)

An integrated assessment of the ADME properties of the CDK4/6 Inhibitor ribociclib utilizing preclinical in vitro, in vivo, and human ADME data
by: Alexander D. James, et al.
Published: (2020-06-01)

Ribociclib for the first-line treatment of advanced hormone receptor-positive breast cancer: a review of subgroup analyses from the MONALEESA-2 trial
by: Gabriel N. Hortobagyi
Published: (2018-10-01)

Expanding the Clinical Use of CDK4/6 Inhibitors in the Treatment of Hormone Receptor-Positive, HER2-Negative Breast Cancer from Metastatic Setting to Adjuvant Setting
by: Abdel-Razeq H, et al.
Published: (2022-03-01)

Ribociclib in newly diagnosed hepatitis B infection: A case report
by: Fabrizio Di Costanzo, et al.
Published: (2023-06-01)

Treatment options for patients with hormone receptor-positive, HER2-negative advanced-stage breast cancer: maintaining cyclin-dependent kinase 4/6 inhibitors beyond progression
by: Malek Horani, et al.
Published: (2023-10-01)

Case Report: Ribociclib-induced phototoxicity presented as dyschromia with subsequent bullae formation
by: Jyun-Yan Jhan, et al.
Published: (2023-08-01)

Effectiveness of cyclin-dependent kinase 4 and 6 inhibitors for the treatment of hormonesensitive HER2-negative metastatic breast cancer in first-line therapy: A systematic literature review
by: N. A. Avxentyev, et al.
Published: (2024-05-01)

Rapid Capillary Electrophoresis Method for Simultaneous Determination of Abemaciclib, Ribociclib, and Palbociclib in Pharmaceutical Dosage Forms: A Green Approach
by: Zvonimir Mlinarić, et al.
Published: (2022-11-01)

Shifting Treatment Paradigms: Improvements in HR-Positive, HER-2- Negative Breast Cancer Care in Poland from a Clinical Perspective
by: Marek Ziobro, et al.
Published: (2023-02-01)